EpiCypher^® and New England Biolabs^® (NEB^®)  announced an expanded strategic partnership to co-develop next-generation tools for epigenomics research. Building on a successful track record of collaboration, the partnership will accelerate the creation of innovative technologies that advance understanding of gene regulation, chromatin biology, and disease mechanisms.

The partnership combines EpiCypher's strengths in chromatin biology, assay development, and epigenomic profiling with NEB's leadership in enzyme innovation, molecular biology, and reagent production to deliver high-performance solutions that enable deeper, more precise insights into epigenetic regulation. NEB has a history of applying its enzymology expertise to such applications and has already developed numerous novel approaches for the study of DNA methylation, hydroxymethylation, the epitranscriptome, chromatin accessibility, and chromatin interactions.

This expanded collaboration builds on a growing portfolio of jointly developed genomic tools, kits, and protocols, some supported in part by NIH SBIR funding. These include solutions for CUT&RUN, CUT&Tag, and NiCE-seq, as well as emerging multiomic workflows, such as Multiomic CUT&RUN and meCUT&RUN, which incorporate NEB's Enzymatic Methyl-seq (EM-seq™) technology. The partnership also extends to long-read sequencing applications, including EpiCypher's recently launched CUTANA^® Fiber-seq kit, which integrates key NEB reagents that helped accelerate its path to market, while supporting strong performance.

As part of the agreement, NEB will distribute EpiCypher's CUTANA portfolio of genomics products in key international markets, beginning with Germany and the United Kingdom, and continuing with additional markets later this year.

"Working closely with the management and technical teams at EpiCypher has revealed a strong alignment  with NEB's values around scientific integrity, innovation, and our shared commitment to equipping researchers with technologies and tools to advance science," said Isaac B. Meek, Director of Corporate and Business Development at NEB. "EpiCypher's leadership in epigenetics and dedication to enabling researchers created an opportunity to collaborate and drive innovation in new and impactful directions."

"Having a strategic partner with NEB's scientific expertise, scale, and market reach allows us to broaden the impact of our technologies worldwide," said Martis Cowles, Ph.D., Chief Business Officer of EpiCypher. "By combining our assay development capabilities with NEB's NGS enzyme and reagent expertise, we can deliver next-generation tools that enable new insights into gene regulation and disease biology."

Together, EpiCypher and NEB are advancing their longstanding scientific collaboration to deliver the next generation of tools for epigenomics research worldwide.